Activity of a novel, dual PI3-kinase/mTor inhibitor NVP-BEZ235 against primary human pancreatic cancers grown as orthotopic xenografts

Abstract

The phosphatidylinositol-3-kinase (PI3K)/Akt signalling pathway is frequently deregulated in pancreatic cancers, and is believed to be an important determinant of their biological aggression and drug resistance. NVP-BEZ235 is a novel, dual class I PI3K/mammalian target of rapamycin (mTor) inhibitor undergoing phase I human clinical trials. To simulate clinical testing, the effects of NVP-BEZ235 were studied in five early passage primary pancreatic cancer xenografts, grown orthotopically. These tumours showed activated PKB/Akt, and increased levels of at least one of the receptor tyrosine kinases that are commonly activated in pancreatic cancers. Pharmacodynamic effects were measured following acute single doses, and anticancer effects were determined in separate groups following chronic drug exposure. Acute oral dosing with NVP-BEZ235 strongly suppressed the phosphorylation of PKB/Akt, followed by recovery over 24 h. There was also inhibition of Ser235/236 S6 ribosomal protein and Thr37/46 4E-BP1, consistent with the effects of NVP-BEZ235 as a dual PI3K/mTor inhibitor. Chronic dosing with 45 mg kg À1 of NVP-BEZ235 was well tolerated, and produced significant tumour growth inhibition in three models. These results predict that agents targeting the PI3K/Akt/mTor pathway might have anticancer activity in pancreatic cancer patients, and support the testing of combination studies involving chemotherapy or other molecular targeted agents.

Activation of AR Sensitizes Breast Carcinomas to NVP-BEZ235's Therapeutic Effect Mediated by PTEN and KLLN Upregulation

“…S7A). Multiple studies have reported that high doses of NVP-BEZ235 resulted in weight loss in mouse models (31,32). After 4 weeks of treatment, NVP-BEZ235 reduced mouse body weight in a dose-dependent manner (Supplementary Fig.…”

NVP-BEZ235, a dual pan class I PI3 kinase and mTOR inhibitor, promotes osteogenic differentiation in human mesenchymal stromal cells

“…Furthermore, BEZ235 displays a 2 log improvement in sensitivity over LY294002 (32) while not affecting other protein kinases. (32,33) BEZ235 exhibits strong antitumor activity in multiple in vitro and preclinical animal models (32,(34)(35)(36)(37) and is currently in phase I-II clinical trials for advanced solid tumors.…”

Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells

“…Hence, the identification and characterization of PI3K pathway inhibitors with good drug-like properties were eagerly awaited to initiate clinical trials (8). NVP-BEZ235 is a dual PI3K/mTOR inhibitor that has proven its ability to significantly reduce the tumor growth of a number of human xenograft models (9)(10)(11), as well as of a murine PIK3CA driven lung tumor model (12). However, it is still unclear if compounds with a dual inhibitory profile would be equally efficacious in cancers with distinct genetic lesions in the PIK3CA, PTEN, HER2, or KRAS genes.…”